31 July 2025

BIOPHARMA CREDIT PLC

(THE "COMPANY")

Appointment of New Director

The Board of Directors of the Company, as part of its proactive succession planning, is pleased to announce the appointment of Nigel Reynolds as a non-executive Director with effect from 1 January 2026, following his retirement from PwC on 31 December 2025.  Mr Reynolds will, after a transition period, take over as chair of the Company's Audit and Risk committee.

Mr Reynolds has 34 years of accounting and finance experience advising both listed and private companies.  He has been a partner at PwC for 20 years specialising in audit, transaction services and capital markets work.  During his time at PwC, he led its London Assurance practice for 5 years, led the private equity portfolio company practice and was the relationship partner for various UK listed and international companies including companies in healthcare and investment trusts.  Over his career he has also advised companies on strategy, M&A, internal audit and tax and has overseen technology, sustainability, and other large projects for PwC clients.

There are no other details required to be disclosed under LR 9.6.13R (1) to (6) of the Financial Conduct Authority Listing Rules.

Enquiries:

BioPharma Credit plc

via MUFG Corporate Governance Limited

Company Secretary

+44 (0) 333 300 1932

Burson Buchanan

Mark Court / Jamie Hooper / Henry Wilson / Nick Croysdill

+44 (0)20 7466 5000

biopharmacredit@buchanan.uk.com

Notes to Editors:

BioPharma Credit PLC is London's only specialist debt investor to the life sciences industry and joined the LSE in March 2017. BioPharma Credit PLC seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. BioPharma Credit PLC seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.